Table of Content

1 INTRODUCTION 29
1.1 STUDY OBJECTIVES 29
1.2 MARKET DEFINITION 29
1.3 MARKET SCOPE 30
1.3.1 MARKETS COVERED AND REGIONS CONSIDERED 30
1.3.2 INCLUSIONS & EXCLUSIONS 31
1.3.3 YEARS CONSIDERED 32
1.3.4 CURRENCY CONSIDERED 32
1.4 MARKET STAKEHOLDERS 32
1.5 SUMMARY OF CHANGES 33
2 RESEARCH METHODOLOGY 34
2.1 RESEARCH DATA 34
2.1.1 SECONDARY DATA 35
2.1.1.1 List of secondary sources 36
2.1.2 PRIMARY DATA 37
2.1.2.1 Key data from primary sources 37
2.2 MARKET ESTIMATION METHODOLOGY 39
2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION 40
2.2.2 USAGE-BASED MARKET ESTIMATION 42
2.2.3 PRIMARY RESEARCH VALIDATION 43
2.3 DATA TRIANGULATION AND MARKET BREAKDOWN 44
2.4 RESEARCH ASSUMPTIONS 45
2.4.1 STUDY ASSUMPTIONS 45
2.5 RESEARCH LIMITATIONS 45
2.6 RISK ASSESSMENT 46
3 EXECUTIVE SUMMARY 47
4 PREMIUM INSIGHTS 51
4.1 RADIOTHERAPY MARKET OVERVIEW 51
4.2 EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION) 52
4.3 EUROPE: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET,
BY TYPE AND REGION (2022) 52
4.4 RADIOTHERAPY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 53
4.5 RADIOTHERAPY MARKET: REGIONAL MIX, 2022–2030 (USD MILLION) 54
?
5 MARKET OVERVIEW 55
5.1 INTRODUCTION 55
5.2 MARKET DYNAMICS 55
5.2.1 DRIVERS 56
5.2.1.1 Advancements in radiotherapy treatment 56
5.2.1.2 Growing patient population 57
5.2.1.3 Increasing initiatives to promote radiotherapy awareness 57
5.2.1.4 Growing use of particle therapy for cancer treatment 58
5.2.2 RESTRAINTS 58
5.2.2.1 Lack of adequate healthcare infrastructure 58
5.2.2.2 High capital cost of radiotherapy 59
5.2.2.3 Complexity of radiotherapy 59
5.2.3 OPPORTUNITIES 60
5.2.3.1 Emerging economies 60
5.2.3.2 Favorable changes in US radiotherapy payment model 60
5.2.3.3 Government and private investments to meet rising demand for cancer treatment 61
5.2.4 CHALLENGES 61
5.2.4.1 Dearth of skilled personnel 61
5.2.4.2 Difficulties in visualizing tumors during radiotherapy 62
5.2.4.3 Risk of radiation exposure 62
5.3 REGULATORY ANALYSIS 63
5.3.1 REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATIONS 63
5.3.2 REGULATORY LANDSCAPE 65
5.3.2.1 North America 65
5.3.2.1.1 US 65
5.3.2.1.2 Canada 66
5.3.2.2 Europe 67
5.3.2.3 Asia Pacific 68
5.3.2.3.1 China 68
5.3.2.3.2 Japan 68
5.3.2.3.3 India 69
5.4 REIMBURSEMENT SCENARIO 70
5.5 VALUE CHAIN ANALYSIS 71
5.5.1 RESEARCH & DEVELOPMENT 72
5.5.2 PROCUREMENT & PRODUCT DEVELOPMENT 72
5.5.3 MARKETING, SALES, AND DISTRIBUTION 72
5.6 SUPPLY CHAIN ANALYSIS 73
5.6.1 PROMINENT COMPANIES 73
5.6.2 SMALL & MEDIUM-SIZED ENTERPRISES 73
5.6.3 END USERS 73
5.7 ECOSYSTEM ANALYSIS 74
5.8 PORTER’S FIVE FORCES ANALYSIS 75
5.8.1 INTENSITY OF COMPETITIVE RIVALRY 76
5.8.2 BARGAINING POWER OF SUPPLIERS 76
5.8.3 BARGAINING POWER OF BUYERS 76
5.8.4 THREAT OF SUBSTITUTES 76
5.8.5 THREAT OF NEW ENTRANTS 76
5.9 KEY STAKEHOLDERS & BUYING CRITERIA 77
5.9.1 KEY STAKEHOLDERS IN BUYING PROCESS 77
5.9.2 KEY BUYING CRITERIA 78
5.10 TRADE ANALYSIS 79
5.10.1 IMPORT DATA 79
5.10.2 EXPORT DATA 80
5.11 PATENT ANALYSIS 81
5.12 PRICING ANALYSIS 83
5.12.1 AVERAGE SELLING PRICE, BY PRODUCT 83
5.12.2 AVERAGE SELLING PRICE, BY COUNTRY 84
5.13 TECHNOLOGY ANALYSIS 86
5.13.1 KEY TECHNOLOGIES 86
5.13.1.1 Linear accelerators (LINACs) 86
5.13.1.2 Image-guided radiotherapy (IGRT) 86
5.13.1.3 Intensity-modulated radiotherapy (IMRT) 86
5.13.1.4 Particle therapy 86
5.13.1.5 Surface-guided radiotherapy (SGRT) 87
5.13.2 COMPLEMENTARY TECHNOLOGIES 87
5.13.2.1 Chemotherapy 87
5.13.2.2 Immunotherapy 87
5.13.2.3 Hyperthermia therapy 87
5.13.3 ADJACENT TECHNOLOGIES 88
5.13.3.1 Medical imaging technologies 88
5.13.3.2 Radioisotope production technologies 88
5.13.3.3 Systematic radiotherapy 88
5.13.3.4 Theranostics 89
5.14 CASE STUDY ANALYSIS 89
5.15 KEY CONFERENCES & EVENTS, 2024–2025 89
5.16 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 91
5.17 INVESTMENT & FUNDING SCENARIO 91
5.18 UNMET NEEDS 93
5.19 IMPACT OF GENERATIVE AI ON RADIOTHERAPY MARKET 94
?
6 RADIOTHERAPY MARKET, BY SYSTEM AND SOFTWARE & SERVICE 95
6.1 INTRODUCTION 96
6.2 SYSTEMS 96
6.2.1 CONTINUOUS DEVELOPMENT OF ADVANCED TECHNOLOGIES TO BOOST MARKET 96
6.3 SOFTWARE & SERVICES 97
6.3.1 INCREASING DEMAND FOR PRECISE AND EFFECTIVE CANCER TREATMENT TO SUPPORT MARKET GROWTH 97
7 RADIOTHERAPY MARKET, BY TECHNOLOGY 99
7.1 INTRODUCTION 100
7.2 EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES 100
7.2.1 LINACS 101
7.2.1.1 Conventional LINACs 102
7.2.1.1.1 Long treatment duration to limit adoption 102
7.2.1.2 Stereotactic advanced electron/cobalt-60 LINACs 103
7.2.1.2.1 CyberKnife 104
7.2.1.2.1.1 Precise radiation delivery with robotic correction capabilities to drive market 104
7.2.1.2.2 Gamma Knife 105
7.2.1.2.2.1 Ongoing product development and launches to support growth 105
7.2.1.2.3 TomoTherapy 106
7.2.1.2.3.1 High installation and maintenance costs to limit adoption 106
7.2.1.3 MRI LINACs 107
7.2.1.3.1 Real-time imaging advantage to propel growth 107
7.2.2 PARTICLE THERAPY 108
7.2.2.1 Cyclotrons 109
7.2.2.1.1 Enhanced outcomes and other advantages to boost adoption 109
7.2.2.2 Synchrotrons 110
7.2.2.2.1 Increasing investments in synchrotron facilities to drive market 110
7.2.2.3 Synchrocyclotrons 110
7.2.2.3.1 High space requirements to limit widespread adoption 110
7.2.3 CONVENTIONAL COBALT-60 TELETHERAPY 111
7.2.3.1 Complex dose delivery planning and radiation exposure to limit market adoption 111
7.3 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY 112
7.3.1 SEEDS 113
7.3.1.1 Adverse side-effects associated with seeds to limit adoption 113
7.3.2 AFTERLOADERS 114
7.3.2.1 Proper positioning and better control of isotopes in modern afterloaders to drive demand 114
7.3.3 IORT SYSTEMS 115
7.3.3.1 Rising adoption of electronic brachytherapy procedures to support growth 115
7.3.4 APPLICATORS 116
7.3.4.1 High risk of radiation exposure in manual applicators to limit growth 116
8 RADIOTHERAPY MARKET, BY APPLICATION 118
8.1 INTRODUCTION 119
8.2 EXTERNAL BEAM RADIOTHERAPY APPLICATIONS 119
8.2.1 PROSTATE CANCER 120
8.2.1.1 High incidence rate and efficiency of EBRT in prostate cancer treatment to support growth 120
8.2.2 BREAST CANCER 121
8.2.2.1 Therapeutic benefits of EBRT to drive market 121
8.2.3 LUNG CANCER 122
8.2.3.1 High prevalence of lung cancer and efficiency of EBRT to drive market 122
8.2.4 HEAD & NECK CANCER 123
8.2.4.1 Noninvasive treatment of head & neck cancers to drive market 123
8.2.5 COLORECTAL CANCER 124
8.2.5.1 High incidence of colorectal cancer to support market growth 124
8.2.6 OTHER EXTERNAL BEAM RADIOTHERAPY APPLICATIONS 125
8.3 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS 126
8.3.1 PROSTATE CANCER 128
8.3.1.1 Precision of brachytherapy to drive market 128
8.3.2 GYNECOLOGICAL CANCER 129
8.3.2.1 Availability of alternatives to hinder adoption of brachytherapy 129
8.3.3 BREAST CANCER 129
8.3.3.1 Wide usage as replacement for traditional EBRT to drive market 129
8.3.4 CERVICAL CANCER 130
8.3.4.1 Effectiveness of combined brachytherapy-chemotherapy procedures to support adoption 130
8.3.5 PENILE CANCER 131
8.3.5.1 Rising awareness and effectiveness of brachytherapy to drive market 131
8.3.6 OTHER INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS 132
9 RADIOTHERAPY MARKET, BY PROCEDURE 134
9.1 INTRODUCTION 135
9.2 EXTERNAL BEAM RADIOTHERAPY 135
9.2.1 IMAGE-GUIDED RADIOTHERAPY 136
9.2.1.1 Growing demand in treating deep-seated tumors to drive market 136
9.2.2 INTENSITY-MODULATED RADIOTHERAPY 137
9.2.2.1 Advantages over 2D and 3D-CRT to boost adoption 137
?
9.2.3 3D CONFORMAL RADIOTHERAPY 138
9.2.3.1 High precision and minimal damage to nearby tissues to boost adoption 138
9.2.4 STEREOTACTIC RADIOTHERAPY 139
9.2.4.1 Minimally invasive procedure to drive end-user preference 139
9.2.5 PARTICLE THERAPY 140
9.2.5.1 High usage as primary mode of cancer treatment to sustain market growth 140
9.2.6 OTHER EXTERNAL BEAM RADIOTHERAPY PROCEDURES 141
9.3 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY 142
9.3.1 LDR BRACHYTHERAPY 143
9.3.1.1 Low risk of radiation exposure to surrounding tissues to drive adoption 143
9.3.2 HDR BRACHYTHERAPY 144
9.3.2.1 Possibility of tissue injury to affect adoption 144
9.3.3 PDR BRACHYTHERAPY 145
9.3.3.1 Combination of advantages to boost growth 145
10 RADIOTHERAPY MARKET, BY END USER 146
10.1 INTRODUCTION 147
10.2 HOSPITALS 147
10.2.1 HOSPITALS TO DOMINATE END-USER MARKET 147
10.3 INDEPENDENT RADIOTHERAPY CENTERS 148
10.3.1 LOWER OPERATING COSTS AND CONVENIENCE TO SUPPORT MARKET GROWTH 148
11 RADIOTHERAPY MARKET, BY REGION 150
11.1 INTRODUCTION 151
11.2 NORTH AMERICA 153
11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 158
11.2.2 US 159
11.2.2.1 Changes in reimbursement scenario to drive growth 159
11.2.3 CANADA 161
11.2.3.1 Favorable initiatives from government and private organizations to boost market 161
11.3 EUROPE 163
11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 168
11.3.2 GERMANY 169
11.3.2.1 Availability of novel radiotherapy products to drive market 169
11.3.3 FRANCE 171
11.3.3.1 Presence of advanced healthcare system to augment growth 171
11.3.4 UK 173
11.3.4.1 High incidence of cancer to drive market 173
?
11.3.5 SPAIN 175
11.3.5.1 Growing research activities on cancer care to promote growth 175
11.3.6 ITALY 177
11.3.6.1 Rising clinical trials and research activities in hospitals and universities to support growth 177
11.3.7 REST OF EUROPE 179
11.4 ASIA PACIFIC 180
11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 187
11.4.2 JAPAN 187
11.4.2.1 Rising geriatric population to encourage growth 187
11.4.3 CHINA 189
11.4.3.1 Growing partnerships among market players to support growth 189
11.4.4 INDIA 191
11.4.4.1 Increasing preference for minimally invasive treatment to propel market 191
11.4.5 SOUTH KOREA 193
11.4.5.1 Increasing incidence of cancer to support market 193
11.4.6 AUSTRALIA 195
11.4.6.1 Growing cancer cases to fuel market 195
11.4.7 REST OF ASIA PACIFIC 197
11.5 LATIN AMERICA 199
11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 204
11.5.2 BRAZIL 204
11.5.2.1 Increasing prevalence of cancer to fuel market 204
11.5.3 MEXICO 206
11.5.3.1 Rising target population to boost market growth 206
11.5.4 REST OF LATIN AMERICA 208
11.6 MIDDLE EAST & AFRICA 210
11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 215
11.6.2 GCC COUNTRIES 215
11.6.2.1 Booming medical tourism to expedite growth 215
11.6.3 REST OF MIDDLE EAST & AFRICA 217
12 COMPETITIVE LANDSCAPE 219
12.1 INTRODUCTION 219
12.2 KEY PLAYER STRATEGY/RIGHT TO WIN 219
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN RADIOTHERAPY MARKET 219
12.3 REVENUE ANALYSIS, 2019–2023 221
12.4 MARKET SHARE ANALYSIS, 2023 221
12.4.1 EXTERNAL BEAM RADIOTHERAPY MARKET RANKING 223
12.4.2 INTERNAL BEAM RADIOTHERAPY MARKET RANKING 224
?
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 224
12.5.1 STARS 224
12.5.2 EMERGING LEADERS 224
12.5.3 PERVASIVE PLAYERS 225
12.5.4 PARTICIPANTS 225
12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 226
12.5.5.1 Company footprint 226
12.5.5.2 Technology footprint 227
12.5.5.3 Application footprint 228
12.5.5.4 End-user footprint 229
12.5.5.5 Region footprint 229
12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 230
12.6.1 PROGRESSIVE COMPANIES 230
12.6.2 RESPONSIVE COMPANIES 230
12.6.3 DYNAMIC COMPANIES 230
12.6.4 STARTING BLOCKS 231
12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 232
12.7 COMPANY VALUATION & FINANCIAL METRICS 234
12.8 BRAND/PRODUCT COMPARISON 235
12.9 COMPETITIVE SCENARIO 236
12.9.1 PRODUCT LAUNCHES AND APPROVALS 236
12.9.2 DEALS 237
12.9.3 EXPANSIONS 238
13 COMPANY PROFILES 239
13.1 KEY PLAYERS 239
13.1.1 SIEMENS HEALTHINEERS AG (VARIAN MEDICAL SYSTEMS, INC.) 239
13.1.1.1 Business overview 239
13.1.1.2 Products/Services/Solutions offered 240
13.1.1.3 Recent developments 242
13.1.1.3.1 Product approvals 242
13.1.1.3.2 Deals 242
13.1.1.4 MnM view 244
13.1.1.4.1 Key strengths 244
13.1.1.4.2 Strategic choices 244
13.1.1.4.3 Weaknesses & competitive threats 244
13.1.2 ELEKTA 245
13.1.2.1 Business overview 245
13.1.2.2 Products/Services/Solutions offered 246
13.1.2.3 Recent developments 247
13.1.2.3.1 Product launches and approvals 247
13.1.2.3.2 Deals 248
13.1.2.3.3 Expansions 250
13.1.2.4 MnM view 250
13.1.2.4.1 Key strengths 250
13.1.2.4.2 Strategic choices 250
13.1.2.4.3 Weaknesses & competitive threats 250
13.1.3 ACCURAY INCORPORATED 251
13.1.3.1 Business overview 251
13.1.3.2 Products/Services/Solutions offered 252
13.1.3.3 Recent developments 253
13.1.3.3.1 Product approvals 253
13.1.3.3.2 Deals 254
13.1.3.3.3 Expansions 255
13.1.3.4 MnM view 255
13.1.3.4.1 Key strengths 255
13.1.3.4.2 Strategic choices 255
13.1.3.4.3 Weaknesses & competitive threats 255
13.1.4 IBA WORLDWIDE 256
13.1.4.1 Business overview 256
13.1.4.2 Products/Services/Solutions offered 257
13.1.4.3 Recent developments 258
13.1.4.3.1 Products launches 258
13.1.4.3.2 Deals 259
13.1.4.4 MnM view 260
13.1.4.4.1 Key strengths 260
13.1.4.4.2 Strategic choices 260
13.1.4.4.3 Weaknesses & competitive threats 260
13.1.5 VIEWRAY, INC. 261
13.1.5.1 Business overview 261
13.1.5.2 Products/Services/Solutions offered 262
13.1.5.3 Recent developments 263
13.1.5.3.1 Product approvals 263
13.1.5.3.2 Deals 263
13.1.6 BRAINLAB AG 265
13.1.6.1 Business overview 265
13.1.6.2 Products/Services/Solutions offered 265
13.1.7 PERSPECTIVE THERAPEUTICS 266
13.1.7.1 Business overview 266
13.1.7.2 Products/Services/Solutions offered 267
13.1.7.3 Recent developments 268
13.1.7.3.1 Deals 268
?
13.1.8 HITACHI LTD. (HITACHI HIGH-TECH CORPORATION) 269
13.1.8.1 Business overview 269
13.1.8.2 Products/Services/Solutions offered 270
13.1.8.3 Recent developments 271
13.1.8.3.1 Deals 271
13.1.9 SUMITOMO HEAVY INDUSTRIES, LTD. 272
13.1.9.1 Business overview 272
13.1.9.2 Products/Services/Solutions offered 273
13.1.9.3 Recent developments 274
13.1.9.3.1 Product launches 274
13.1.9.3.2 Other developments 274
13.1.10 CARL ZEISS MEDITEC AG (WHOLLY OWNED SUBSIDIARY OF CARL ZEISS AG) 275
13.1.10.1 Business overview 275
13.1.10.2 Products/Services/Solutions offered 277
13.1.10.3 Recent developments 277
13.1.10.3.1 Products launches 277
13.1.11 MIM SOFTWARE INC. 278
13.1.11.1 Business overview 278
13.1.11.2 Products/Services/Solutions offered 278
13.1.11.3 Recent developments 279
13.1.11.3.1 Product launches and approvals 279
13.1.11.3.2 Deals 279
13.1.12 PANACEA MEDICAL TECHNOLOGIES PVT. LTD. 280
13.1.12.1 Business overview 280
13.1.12.2 Products/Services/Solutions offered 280
13.1.12.3 Recent developments 281
13.1.12.3.1 Product launches and approvals 281
13.1.13 PROVISION HEALTHCARE 282
13.1.13.1 Business overview 282
13.1.13.2 Products/Services/Solutions offered 282
13.1.14 MEVION MEDICAL SYSTEMS 283
13.1.14.1 Business overview 283
13.1.14.2 Products/Services/Solutions offered 283
13.1.14.3 Recent developments 284
13.1.14.3.1 Product launches 284
13.1.14.3.2 Deals 284
13.1.15 RAYSEARCH LABORATORIES 286
13.1.15.1 Business overview 286
13.1.15.2 Products/Services/Solutions offered 287
13.1.15.3 Recent developments 288
13.1.15.3.1 Product launches 288
13.1.15.3.2 Deals 288
13.1.16 KONINKLIJKE PHILIPS N.V. 290
13.1.16.1 Business overview 290
13.1.16.2 Products/Services/Solutions offered 291
13.1.16.3 Recent developments 292
13.1.16.3.1 Product launches 292
13.1.16.3.2 Deals 292
13.2 OTHER PLAYERS 293
13.2.1 INTRAOP MEDICAL, INC. 293
13.2.2 OPTIVUS PROTON THERAPY, INC. 294
13.2.3 BEBIG MEDICAL 295
13.2.4 P-CURE 296
13.2.5 THERAGENICS CORPORATION 297
13.2.6 PROTOM INTERNATIONAL 298
13.2.7 DOS ISOFT SA 299
13.2.8 ISOAID, LLC 300
13.2.9 MAGNETTX ONCOLOGY SOLUTIONS LTD. 301
14 APPENDIX 302
14.1 DISCUSSION GUIDE 302
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS? SUBSCRIPTION PORTAL 309
14.3 CUSTOMIZATION OPTIONS 311
14.4 RELATED REPORTS 311
14.5 AUTHOR DETAILS 312



List of Figures

FIGURE 1 RESEARCH DESIGN 34
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION AND REGION 38
FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 40
FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (2023) 42
FIGURE 5 RADIOTHERAPY MARKET: MARKET SIZE ESTIMATION METHODOLOGY 43
FIGURE 6 DATA TRIANGULATION METHODOLOGY 44
FIGURE 7 RADIOTHERAPY MARKET, BY SYSTEM AND SOFTWARE & SERVICE 2024 VS. 2030 (USD MILLION) 47
FIGURE 8 RADIOTHERAPY MARKET, BY TECHNOLOGY, 2024 VS. 2030 (USD MILLION) 48
FIGURE 9 EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET, BY TYPE 2024 VS. 2030 (USD MILLION) 48
FIGURE 10 RADIOTHERAPY MARKET SHARE, BY END USER, 2024 VS. 2030(%) 49
FIGURE 11 RADIOTHERAPY MARKET: REGIONAL SNAPSHOT 50
FIGURE 12 RISING CANCER PREVALENCE WORLDWIDE TO DRIVE MARKET GROWTH 51
FIGURE 13 INTENSITY-MODULATED RADIATION THERAPY TO HOLD LARGEST
SHARE OF MARKET IN 2024 52
FIGURE 14 LINACS HELD LARGEST SHARE OF EUROPEAN MARKET IN 2O23 52
FIGURE 15 CHINA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 53
FIGURE 16 NORTH AMERICA WILL CONTINUE TO DOMINATE RADIOTHERAPY MARKET DURING FORECAST PERIOD 54
FIGURE 17 RADIOTHERAPY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES 55
FIGURE 18 PROJECTED INCREASE IN CANCER CASES, 2020 VS. 2040 57
FIGURE 19 RADIOTHERAPY MARKET: VALUE CHAIN ANALYSIS 72
FIGURE 20 RADIOTHERAPY MARKET: SUPPLY CHAIN ANALYSIS 73
FIGURE 21 RADIOTHERAPY MARKET: ECOSYSTEM ANALYSIS 74
FIGURE 22 RADIOTHERAPY MARKET: PORTER’S FIVE FORCES ANALYSIS 75
FIGURE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF RADIOTHERAPY 77
FIGURE 24 KEY BUYING CRITERIA FOR RADIOTHERAPY 78
FIGURE 25 RADIOTHERAPY MARKET: TOP PATENT OWNERS/PATENTING TRENDS FOR PROTON BEAM THERAPY IN RECENT YEARS 81
FIGURE 26 RADIOTHERAPY MARKET: TOP PATENT OWNERS/PATENTING TRENDS FOR MEDICAL LINEAR ACCELERATORS IN RECENT YEARS 82
FIGURE 27 AVERAGE SELLING PRICE, BY PRODUCT, 2023 (USD) 83
FIGURE 28 AVERAGE SELLING PRICE OF RADIOTHERAPY PRODUCTS, BY COUNTRY 2023 (USD) 84
FIGURE 29 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 91
FIGURE 30 RADIOTHERAPY MARKET: NUMBER OF DEALS, BY KEY PLAYER 2019–2023 (USD MILLION) 92
FIGURE 31 RADIOTHERAPY MARKET: NUMBER OF INVESTOR DEALS, BY KEY PLAYER 2019–2023 (USD MILLION) 92
FIGURE 32 VALUE OF INVESTOR DEALS IN RADIOTHERAPY MARKET, BY KEY PLAYER 2019–2023 (USD MILLION) 93
FIGURE 33 USE OF GEN AI IN RADIOTHERAPY MARKET 94
FIGURE 34 NORTH AMERICA: RADIOTHERAPY MARKET SNAPSHOT 153
FIGURE 35 ASIA PACIFIC: RADIOTHERAPY MARKET SNAPSHOT 181
FIGURE 36 REVENUE ANALYSIS OF KEY PLAYERS IN RADIOTHERAPY MARKET (2019?2023) 221
FIGURE 37 MARKET SHARE ANALYSIS OF KEY PLAYERS IN RADIOTHERAPY MARKET (2023) 222
FIGURE 38 EXTERNAL BEAM RADIOTHERAPY MARKET RANKING, BY KEY PLAYER, 2023 223
FIGURE 39 INTERNAL BEAM RADIOTHERAPY MARKET RANKING, BY KEY PLAYER, 2023 224
FIGURE 40 RADIOTHERAPY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023 225
FIGURE 41 RADIOTHERAPY MARKET: COMPANY FOOTPRINT 226
FIGURE 42 RADIOTHERAPY MARKET: COMPANY EVALUATION MATRIX
(STARTUPS/SMES), 2023 231
FIGURE 43 EV/EBITDA OF KEY VENDORS 234
FIGURE 44 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 234
FIGURE 45 RADIOTHERAPY MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 235
FIGURE 46 SIEMENS HEALTHINEERS AG (VARIAN MEDICAL SYSTEMS, INC.):
COMPANY SNAPSHOT 240
FIGURE 47 ELEKTA: COMPANY SNAPSHOT 246
FIGURE 48 ACCURAY INCORPORATED: COMPANY SNAPSHOT 252
FIGURE 49 IBA WORLDWIDE: COMPANY SNAPSHOT 257
FIGURE 50 VIEWRAY, INC.: COMPANY SNAPSHOT 262
FIGURE 51 PERSPECTIVE THERAPEUTICS: COMPANY SNAPSHOT 267
FIGURE 52 HITACHI LTD. (HITACHI HIGH-TECH CORPORATION): COMPANY SNAPSHOT 270
FIGURE 53 SUMITOMO HEAVY INDUSTRIES, LTD.: COMPANY SNAPSHOT 273
FIGURE 54 CARL ZEISS MEDITEC AG (WHOLLY OWNED SUBSIDIARY OF CARL ZEISS AG): COMPANY SNAPSHOT 276
FIGURE 55 RAYSEARCH LABORATORIES: COMPANY SNAPSHOT 287
FIGURE 56 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT 291

List of Tables

TABLE 1 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 63
TABLE 2 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 63
TABLE 3 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 64
TABLE 4 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 64
TABLE 5 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 64
TABLE 6 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 66
TABLE 7 CLASS II PRESCRIBED EQUIPMENT CERTIFICATES 66
TABLE 8 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA 68
TABLE 9 INDIA: MEDICAL DEVICE CLASSIFICATION UNDER CDSCO 69
TABLE 10 CPT CODES FOR MAJOR RADIOTHERAPY TREATMENT MODALITIES 70
TABLE 11 REIMBURSEMENT FOR RADIOTHERAPY PROCEDURES PER COURSE 2021 VS. 2022 70
TABLE 12 OPPS TECHNICAL PER PROCEDURE NATIONAL AVERAGE MEDICARE REIMBURSEMENT, 2021 VS. 2022 71
TABLE 13 FREESTANDING PER COURSE NATIONAL AVERAGE MEDICARE REIMBURSEMENT, 2021 VS. 2022 71
TABLE 14 RADIOTHERAPY MARKET: PORTER’S FIVE FORCES ANALYSIS 75
TABLE 15 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF RADIOTHERAPY DEVICES 77
TABLE 16 KEY BUYING CRITERIA FOR RADIOTHERAPY 78
TABLE 17 IMPORT DATA FOR LINACS (HS CODE 902214), BY COUNTRY, 2019?2023 (USD) 79
TABLE 18 EXPORT DATA FOR LINACS (HS CODE 902214), BY COUNTRY, 2019?2023 (USD) 80
TABLE 19 AVERAGE SELLING PRICE RANGE OF KEY PLAYERS FOR TOP TWO PRODUCTS (USD) 84
TABLE 20 AVERAGE SELLING PRICE TREND OF RADIOTHERAPY PRODUCTS, BY REGION, 2021–2023 85
TABLE 21 CASE STUDY: ENHANCING PATIENT SAFETY?SBRT’S ROLE IN MINIMIZING RADIATION RISK IN AN ELDERLY PATIENT (90-YEAR-OLD FEMALE WITH A MEDICALLY INOPERABLE EARLY-STAGE NSCLC) 89
TABLE 22 RADIOTHERAPY MARKET: DETAILED LIST OF MAJOR CONFERENCES & EVENTS 89
TABLE 23 RADIOTHERAPY MARKET: CURRENT UNMET NEEDS 93
TABLE 24 RADIOTHERAPY MARKET, BY SYSTEM AND SOFTWARE & SERVICE 2022–2030 (USD MILLION) 96
TABLE 25 RADIOTHERAPY SYSTEMS MARKET, BY REGION, 2022–2030 (USD MILLION) 97
TABLE 26 RADIOTHERAPY SOFTWARE & SERVICES MARKET, BY REGION 2022–2030 (USD MILLION) 98
TABLE 27 RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 100
TABLE 28 EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY TYPE 2022–2030 (USD MILLION) 101
TABLE 29 EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY REGION 2022–2030 (USD MILLION) 101
TABLE 30 LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION) 102
TABLE 31 LINACS MARKET, BY REGION, 2022–2030 (USD MILLION) 102
TABLE 32 CONVENTIONAL LINACS MARKET, BY REGION, 2022–2030 (USD MILLION) 103
TABLE 33 STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION) 103
TABLE 34 STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINACS MARKET, BY REGION, 2022–2030 (USD MILLION) 104
TABLE 35 CYBERKNIFE MARKET, BY REGION, 2022–2030 (USD MILLION) 105
TABLE 36 GAMMA KNIFE MARKET, BY REGION, 2022–2030 (USD MILLION) 106
TABLE 37 TOMOTHERAPY MARKET, BY REGION, 2022–2030 (USD MILLION) 107
TABLE 38 MRI LINACS MARKET, BY REGION, 2022–2030 (USD MILLION) 107
TABLE 39 PARTICLE THERAPY MARKET, BY SYSTEM TYPE, 2022–2030 (USD MILLION) 108
TABLE 40 PARTICLE THERAPY MARKET, BY REGION, 2022–2030 (USD MILLION) 108
TABLE 41 CYCLOTRONS THERAPY MARKET, BY REGION, 2022–2030 (USD MILLION) 109
TABLE 42 SYNCHROTRONS THERAPY MARKET, BY REGION, 2022–2030 (USD MILLION) 110
TABLE 43 SYNCHROCYCLOTRONS THERAPY MARKET, BY REGION 2022–2030 (USD MILLION) 111
TABLE 44 CONVENTIONAL COBALT-60 TELETHERAPY MARKET, BY REGION 2022–2030 (USD MILLION) 112
TABLE 45 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET BY TYPE, 2022–2030 (USD MILLION) 112
TABLE 46 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET BY REGION, 2022–2030 (USD MILLION) 113
TABLE 47 SEEDS MARKET, BY REGION, 2022–2030 (USD MILLION) 114
TABLE 48 AFTERLOADERS MARKET, BY REGION, 2022–2030 (USD MILLION) 115
TABLE 49 IORT SYSTEMS MARKET, BY REGION, 2022–2030 (USD MILLION) 116
TABLE 50 APPLICATORS MARKET, BY REGION, 2022–2030 (USD MILLION) 117
TABLE 51 RADIOTHERAPY MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 119
TABLE 52 EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET, BY TYPE,
2022–2030 (USD MILLION) 120
TABLE 53 EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET, BY REGION 2022–2030 (USD MILLION) 120
TABLE 54 EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET FOR PROSTATE CANCER, BY REGION, 2022–2030 (USD MILLION) 121
TABLE 55 EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET FOR BREAST CANCER, BY REGION, 2022–2030 (USD MILLION) 122
TABLE 56 EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET FOR LUNG CANCER BY REGION, 2022–2030 (USD MILLION) 123
TABLE 57 EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET FOR HEAD & NECK CANCER, BY REGION, 2022–2030 (USD MILLION) 124
TABLE 58 EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET FOR COLORECTAL CANCER, BY REGION, 2022–2030 (USD MILLION) 125
TABLE 59 OTHER EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET, BY REGION, 2022–2030 (USD MILLION) 126
TABLE 60 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET BY TYPE, 2022–2030 (USD MILLION) 127
TABLE 61 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET BY REGION, 2022–2030 (USD MILLION) 127
TABLE 62 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET FOR PROSTATE CANCER, BY REGION, 2022–2030 (USD MILLION) 128
TABLE 63 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET FOR GYNECOLOGICAL CANCER, BY REGION, 2022–2030 (USD MILLION) 129
TABLE 64 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET FOR BREAST CANCER, BY REGION, 2022–2030 (USD MILLION) 130
TABLE 65 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET FOR CERVICAL CANCER, BY REGION, 2022–2030 (USD MILLION) 131
TABLE 66 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET FOR PENILE CANCER, BY REGION, 2022–2030 (USD MILLION) 132
TABLE 67 OTHER INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET, BY REGION, 2022–2030 (USD MILLION) 133
TABLE 68 RADIOTHERAPY MARKET, BY PROCEDURE, 2022–2030 (USD MILLION) 135
TABLE 69 EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION) 136
TABLE 70 EXTERNAL BEAM RADIOTHERAPY PROCEDURES MARKET, BY REGION 2022–2030 (USD MILLION) 136
TABLE 71 IMAGE-GUIDED RADIOTHERAPY MARKET, BY REGION, 2022–2030 (USD MILLION) 137
TABLE 72 INTENSITY-MODULATED RADIOTHERAPY MARKET, BY REGION 2022–2030 (USD MILLION) 138
TABLE 73 3D CONFORMAL RADIOTHERAPY MARKET, BY REGION 2022–2030 (USD MILLION) 139
TABLE 74 STEREOTACTIC RADIOTHERAPY MARKET, BY REGION, 2022–2030 (USD MILLION) 140
TABLE 75 PARTICLE THERAPY MARKET, BY REGION, 2022–2030 (USD MILLION) 141
TABLE 76 OTHER EBRT PROCEDURES MARKET, BY REGION, 2022–2030 (USD MILLION) 142
TABLE 77 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE 2022–2030 (USD MILLION) 142
TABLE 78 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY REGION 2022–2030 (USD MILLION) 143
TABLE 79 LDR BRACHYTHERAPY MARKET, BY REGION, 2022–2030 (USD MILLION) 144
TABLE 80 HDR BRACHYTHERAPY MARKET, BY REGION, 2022–2030 (USD MILLION) 144
TABLE 81 PDR BRACHYTHERAPY MARKET, BY REGION, 2022–2030 (USD MILLION) 145
TABLE 82 RADIOTHERAPY MARKET, BY END USER, 2022–2030 (USD MILLION) 147
TABLE 83 RADIOTHERAPY MARKET FOR HOSPITALS, BY REGION, 2022–2030 (USD MILLION) 148
TABLE 84 RADIOTHERAPY MARKET FOR INDEPENDENT RADIOTHERAPY CENTERS BY REGION, 2022–2030 (USD MILLION) 149
TABLE 85 RADIOTHERAPY MARKET, BY REGION, 2022–2030 (USD MILLION) 151
TABLE 86 RADIOTHERAPY MARKET: INSTALLED BASE, 2024 (UNITS) 151
TABLE 87 NORTH AMERICA: RADIOTHERAPY MARKET, BY COUNTRY 2022–2030 (USD MILLION) 154
TABLE 88 NORTH AMERICA: RADIOTHERAPY MARKET, BY TECHNOLOGY 2022–2030 (USD MILLION) 154
TABLE 89 NORTH AMERICA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE 2022–2030 (USD MILLION) 154
TABLE 90 NORTH AMERICA: LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION) 155
TABLE 91 NORTH AMERICA: STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION) 155
TABLE 92 NORTH AMERICA: PARTICLE THERAPY MARKET, BY SYSTEM TYPE 2022–2030 (USD MILLION) 155
TABLE 93 NORTH AMERICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET BY TYPE, 2022–2030 (USD MILLION) 156
TABLE 94 NORTH AMERICA: EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET BY TYPE, 2022–2030 (USD MILLION) 156
TABLE 95 NORTH AMERICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET, BY TYPE, 2022–2030 (USD MILLION) 157
TABLE 96 NORTH AMERICA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY PROCEDURE, 2022–2030 (USD MILLION) 157
TABLE 97 NORTH AMERICA: INTERNAL BEAM RADIOTHERAPY /BRACHYTHERAPY PROCEDURE MARKET, BY TYPE, 2022–2030 (USD MILLION) 158
TABLE 98 NORTH AMERICA: RADIOTHERAPY MARKET, BY END USER 2022–2030 (USD MILLION) 158
TABLE 99 NORTH AMERICA: MACROECONOMIC OUTLOOK 158
TABLE 100 NORTH AMERICA: ESTIMATED NUMBER OF NEW CANCER CASES, 2022–2025 159
TABLE 101 US: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 160
TABLE 102 US: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE 2022–2030 (USD MILLION) 160
TABLE 103 US: LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION) 160
TABLE 104 US: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE 2022–2030 (USD MILLION) 161
TABLE 105 CANADA: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 162
TABLE 106 CANADA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE 2022–2030 (USD MILLION) 162
TABLE 107 CANADA: LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION) 162
TABLE 108 CANADA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION) 163
TABLE 109 EUROPE: RADIOTHERAPY MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 164
TABLE 110 EUROPE: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 164
TABLE 111 EUROPE: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE 2022–2030 (USD MILLION) 164
TABLE 112 EUROPE: LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION) 165
TABLE 113 EUROPE: STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINACS MARKET BY TYPE, 2022–2030 (USD MILLION) 165
TABLE 114 EUROPE: PARTICLE THERAPY MARKET, BY SYSTEM TYPE 2022–2030 (USD MILLION) 165
TABLE 115 EUROPE: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION) 166
TABLE 116 EUROPE: EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET, BY TYPE, 2022–2030 (USD MILLION) 166
TABLE 117 EUROPE: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET, BY TYPE, 2022–2030 (USD MILLION) 167
TABLE 118 EUROPE: EXTERNAL BEAM RADIOTHERAPY MARKET, BY PROCEDURE 2022–2030 (USD MILLION) 167
TABLE 119 EUROPE: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY PROCEDURE MARKET, BY TYPE, 2022–2030 (USD MILLION) 168
TABLE 120 EUROPE: RADIOTHERAPY MARKET, BY END USER, 2022–2030 (USD MILLION) 168
TABLE 121 EUROPE: MACROECONOMIC OUTLOOK 169
TABLE 122 EUROPE: ESTIMATED NUMBER OF NEW CANCER CASES, 2022–2025 169
TABLE 123 GERMANY: RADIOTHERAPY MARKET, BY TECHNOLOGY 2022–2030 (USD MILLION) 170
TABLE 124 GERMANY: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE 2022–2030 (USD MILLION) 170
TABLE 125 GERMANY: LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION) 171
TABLE 126 GERMANY: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION) 171
TABLE 127 FRANCE: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 172
TABLE 128 FRANCE: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE 2022–2030 (USD MILLION) 172
TABLE 129 FRANCE: LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION) 172
TABLE 130 FRANCE: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION) 173
TABLE 131 UK: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 173
TABLE 132 UK: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE 2022–2030 (USD MILLION) 174
TABLE 133 UK: LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION) 174
TABLE 134 UK: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE 2022–2030 (USD MILLION) 174
TABLE 135 SPAIN: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 175
TABLE 136 SPAIN: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE 2022–2030 (USD MILLION) 176
TABLE 137 SPAIN: LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION) 176
TABLE 138 SPAIN: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION) 176
TABLE 139 ITALY: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 177
TABLE 140 ITALY: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE 2022–2030 (USD MILLION) 178
TABLE 141 ITALY: LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION) 178
TABLE 142 ITALY: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION) 178
TABLE 143 REST OF EUROPE: RADIOTHERAPY MARKET, BY TECHNOLOGY 2022–2030 (USD MILLION) 179
TABLE 144 REST OF EUROPE: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE 2022–2030 (USD MILLION) 179
TABLE 145 REST OF EUROPE: LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION) 180
TABLE 146 REST OF EUROPE: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET BY TYPE, 2022–2030 (USD MILLION) 180
TABLE 147 ASIA PACIFIC: RADIOTHERAPY MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 182
TABLE 148 ASIA PACIFIC: RADIOTHERAPY MARKET, BY TECHNOLOGY 2022–2030 (USD MILLION) 182
TABLE 149 ASIA PACIFIC: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE 2022–2030 (USD MILLION) 183
TABLE 150 ASIA PACIFIC: LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION) 183
TABLE 151 ASIA PACIFIC: STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION) 184
TABLE 152 ASIA PACIFIC: PARTICLE THERAPY MARKET, BY SYSTEM TYPE 2022–2030 (USD MILLION) 184
TABLE 153 ASIA PACIFIC: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET BY TYPE, 2022–2030 (USD MILLION) 184
TABLE 154 ASIA PACIFIC: EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET, BY TYPE, 2022–2030 (USD MILLION) 185
TABLE 155 ASIA PACIFIC: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET, BY TYPE, 2022–2030 (USD MILLION) 185
TABLE 156 ASIA PACIFIC: EXTERNAL BEAM RADIOTHERAPY MARKET, BY PROCEDURE 2022–2030 (USD MILLION) 186
TABLE 157 ASIA PACIFIC: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY PROCEDURE MARKET, BY TYPE, 2022–2030 (USD MILLION) 186
TABLE 158 ASIA PACIFIC: RADIOTHERAPY MARKET, BY END USER, 2022–2030 (USD MILLION) 186
TABLE 159 ASIA PACIFIC: MACROECONOMIC OUTLOOK 187
TABLE 160 ASIA PACIFIC: ESTIMATED NUMBER OF NEW CANCER CASES, 2022–2025 187
TABLE 161 JAPAN: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 188
TABLE 162 JAPAN: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE 2022–2030 (USD MILLION) 188
TABLE 163 JAPAN: LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION) 188
TABLE 164 JAPAN: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION) 189
TABLE 165 CHINA: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 190
TABLE 166 CHINA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE 2022–2030 (USD MILLION) 190
TABLE 167 CHINA: LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION) 190
TABLE 168 CHINA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION) 191
TABLE 169 INDIA: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 192
TABLE 170 INDIA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE 2022–2030 (USD MILLION) 192
TABLE 171 INDIA: LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION) 192
TABLE 172 INDIA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION) 193
TABLE 173 SOUTH KOREA: RADIOTHERAPY MARKET, BY TECHNOLOGY 2022–2030 (USD MILLION) 194
TABLE 174 SOUTH KOREA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE 2022–2030 (USD MILLION) 194
TABLE 175 SOUTH KOREA: LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION) 195
TABLE 176 SOUTH KOREA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET BY TYPE, 2022–2030 (USD MILLION) 195
TABLE 177 AUSTRALIA: RADIOTHERAPY MARKET, BY TECHNOLOGY 2022–2030 (USD MILLION) 196
TABLE 178 AUSTRALIA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE 2022–2030 (USD MILLION) 196
TABLE 179 AUSTRALIA: LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION) 197
TABLE 180 AUSTRALIA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION) 197
TABLE 181 REST OF ASIA PACIFIC: RADIOTHERAPY MARKET, BY TECHNOLOGY 2022–2030 (USD MILLION) 198
TABLE 182 REST OF ASIA PACIFIC: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE 2022–2030 (USD MILLION) 198
TABLE 183 REST OF ASIA PACIFIC: LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION) 198
TABLE 184 REST OF ASIA PACIFIC: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION) 199
TABLE 185 LATIN AMERICA: RADIOTHERAPY MARKET, BY COUNTRY 2022–2030 (USD MILLION) 199
TABLE 186 LATIN AMERICA: RADIOTHERAPY MARKET, BY TECHNOLOGY 2022–2030 (USD MILLION) 200
TABLE 187 LATIN AMERICA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE 2022–2030 (USD MILLION) 200
TABLE 188 LATIN AMERICA: LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION) 200
TABLE 189 LATIN AMERICA: STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION) 201
TABLE 190 LATIN AMERICA: PARTICLE THERAPY MARKET, BY SYSTEM TYPE 2022–2030 (USD MILLION) 201
TABLE 191 LATIN AMERICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET BY TYPE, 2022–2030 (USD MILLION) 201
TABLE 192 LATIN AMERICA: EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET BY TYPE, 2022–2030 (USD MILLION) 202
TABLE 193 LATIN AMERICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET, BY TYPE, 2022–2030 (USD MILLION) 202
TABLE 194 LATIN AMERICA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY PROCEDURE, 2022–2030 (USD MILLION) 203
TABLE 195 LATIN AMERICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY PROCEDURE MARKET, BY TYPE, 2022–2030 (USD MILLION) 203
TABLE 196 LATIN AMERICA: RADIOTHERAPY MARKET, BY END USER 2022–2030 (USD MILLION) 203
TABLE 197 LATIN AMERICA: MACROECONOMIC OUTLOOK 204
TABLE 198 LATIN AMERICA: ESTIMATED NUMBER OF NEW CANCER CASES, 2022–2025 204
TABLE 199 BRAZIL: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 205
TABLE 200 BRAZIL: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE 2022–2030 (USD MILLION) 205
TABLE 201 BRAZIL: LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION) 205
TABLE 202 BRAZIL: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION) 206
TABLE 203 MEXICO: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 206
TABLE 204 MEXICO: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE 2022–2030 (USD MILLION) 207
TABLE 205 MEXICO: LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION) 207
TABLE 206 MEXICO: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION) 207
TABLE 207 REST OF LATIN AMERICA: RADIOTHERAPY MARKET, BY TECHNOLOGY 2022–2030 (USD MILLION) 208
TABLE 208 REST OF LATIN AMERICA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION) 208
TABLE 209 REST OF LATIN AMERICA: LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION) 209
TABLE 210 REST OF LATIN AMERICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION) 209
TABLE 211 MIDDLE EAST & AFRICA: RADIOTHERAPY MARKET, BY REGION 2022–2030 (USD MILLION) 210
TABLE 212 MIDDLE EAST & AFRICA: RADIOTHERAPY MARKET, BY TECHNOLOGY 2022–2030 (USD MILLION) 211
TABLE 213 MIDDLE EAST & AFRICA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION) 211
TABLE 214 MIDDLE EAST & AFRICA: LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION) 211
TABLE 215 MIDDLE EAST & AFRICA: STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION) 212
TABLE 216 MIDDLE EAST & AFRICA: PARTICLE THERAPY MARKET, BY TYPE 2022–2030 (USD MILLION) 212
TABLE 217 MIDDLE EAST & AFRICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION) 212
TABLE 218 MIDDLE EAST & AFRICA: EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET, BY TYPE, 2022–2030 (USD MILLION) 213
TABLE 219 MIDDLE EAST & AFRICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET, BY TYPE, 2022–2030 (USD MILLION) 213
TABLE 220 MIDDLE EAST & AFRICA: EXTERNAL BEAM RADIOTHERAPY MARKET BY PROCEDURE, 2022–2030 (USD MILLION) 214
TABLE 221 MIDDLE EAST & AFRICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY PROCEDURE MARKET, BY TYPE, 2022–2030 (USD MILLION) 214
TABLE 222 MIDDLE EAST & AFRICA: RADIOTHERAPY MARKET, BY END USER 2022–2030 (USD MILLION) 214
TABLE 223 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK 215
TABLE 224 MIDDLE EAST & AFRICA: ESTIMATED NUMBER OF NEW CANCER CASES 2022–2025 215
TABLE 225 GCC COUNTRIES: RADIOTHERAPY MARKET, BY TECHNOLOGY 2022–2030 (USD MILLION) 216
TABLE 226 GCC COUNTRIES: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE 2022–2030 (USD MILLION) 216
TABLE 227 GCC COUNTRIES: LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION) 216
TABLE 228 GCC COUNTRIES: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET BY TYPE, 2022–2030 (USD MILLION) 217
TABLE 229 REST OF MIDDLE EAST & AFRICA: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 217
TABLE 230 REST OF MIDDLE EAST & AFRICA: EXTERNAL BEAM RADIOTHERAPY MARKET BY TYPE, 2022–2030 (USD MILLION) 218
TABLE 231 REST OF MIDDLE EAST & AFRICA: LINACS MARKET, BY TYPE 2022–2030 (USD MILLION) 218
TABLE 232 REST OF MIDDLE EAST & AFRICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION) 218
TABLE 233 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN
RADIOTHERAPY MARKET 219
TABLE 234 RADIOTHERAPY MARKET: DEGREE OF COMPETITION 222
TABLE 235 RADIOTHERAPY MARKET: TECHNOLOGY FOOTPRINT 227
TABLE 236 RADIOTHERAPY MARKET: APPLICATION FOOTPRINT 228
TABLE 237 RADIOTHERAPY MARKET: END-USER FOOTPRINT 229
TABLE 238 RADIOTHERAPY MARKET: REGION FOOTPRINT 229
TABLE 239 RADIOTHERAPY MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS 232
TABLE 240 RADIOTHERAPY MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS 233
TABLE 241 RADIOTHERAPY MARKET: PRODUCT LAUNCHES AND APPROVALS JANUARY 2021–OCTOBER 2024 236
TABLE 242 RADIOTHERAPY MARKET: DEALS, JANUARY 2021–OCTOBER 2024 237
TABLE 243 RADIOTHERAPY MARKET: EXPANSIONS, JANUARY 2021–OCTOBER 2024 238
TABLE 244 SIEMENS HEALTHINEERS AG (VARIAN MEDICAL SYSTEMS, INC.):
COMPANY OVERVIEW 239
TABLE 245 SIEMENS HEALTHINEERS AG (VARIAN MEDICAL SYSTEMS, INC.): PRODUCTS/SERVICES/SOLUTIONS OFFERED 240
TABLE 246 SIEMENS HEALTHINEERS AG (VARIAN MEDICAL SYSTEMS, INC.):
PRODUCT APPROVALS, JANUARY 2021–OCTOBER 2024 242
TABLE 247 SIEMENS HEALTHINEERS AG (VARIAN MEDICAL SYSTEMS, INC.):
DEALS, JANUARY 2021? OCTOBER 2024 242
TABLE 248 ELEKTA: COMPANY OVERVIEW 245
TABLE 249 ELEKTA: PRODUCTS/SERVICES/SOLUTIONS OFFERED 246
TABLE 250 ELEKTA: PRODUCTS LAUNCHES AND APPROVALS, JANUARY 2021?OCTOBER 2024 247
TABLE 251 ELEKTA: DEALS, JANUARY 2021?OCTOBER 2024 248
TABLE 252 ELEKTA: EXPANSIONS, JANUARY 2021? OCTOBER 2024 250
TABLE 253 ACCURAY INCORPORATED: COMPANY OVERVIEW 251
TABLE 254 ACCURAY INCORPORATED: PRODUCTS/SERVICES/SOLUTIONS OFFERED 252
TABLE 255 ACCURAY INCORPORATED: PRODUCT APPROVALS JANUARY 2021?OCTOBER 2024 253
TABLE 256 ACCURAY INCORPORATED: DEALS, JANUARY 2021?OCTOBER 2024 254
TABLE 257 ACCURAY INCORPORATED: EXPANSIONS, JANUARY 2021? OCTOBER 2024 255
TABLE 258 IBA WORLDWIDE: COMPANY OVERVIEW 256
TABLE 259 IBA WORLDWIDE: PRODUCTS/SERVICES/SOLUTIONS OFFERED 257
TABLE 260 IBA WORLDWIDE: PRODUCT LAUNCHES, JANUARY 2021?OCTOBER 2024 258
TABLE 261 IBA WORLDWIDE: DEALS, JANUARY 2021?OCTOBER 2024 259
TABLE 262 VIEWRAY, INC.: COMPANY OVERVIEW 261
TABLE 263 VIEWRAY, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 262
TABLE 264 VIEWRAY, INC.: PRODUCT APPROVALS, JANUARY 2021?OCTOBER 2024 263
TABLE 265 VIEWRAY, INC.: DEALS, JANUARY 2021?OCTOBER 2024 263
TABLE 266 BRAINLAB AG: COMPANY OVERVIEW 265
TABLE 267 BRAINLAB AG: PRODUCTS/SERVICES/SOLUTIONS OFFERED 265
TABLE 268 PERSPECTIVE THERAPEUTICS: COMPANY OVERVIEW 266
TABLE 269 PERSPECTIVE THERAPEUTICS: PRODUCTS/SERVICES/SOLUTIONS OFFERED 267
TABLE 270 PERSPECTIVE THERAPEUTICS: DEALS, JANUARY 2021?OCTOBER 2024 268
TABLE 271 HITACHI LTD. (HITACHI HIGH-TECH CORPORATION): COMPANY OVERVIEW 269
TABLE 272 HITACHI LTD. (HITACHI HIGH-TECH CORPORATION): PRODUCTS/SERVICES/SOLUTIONS OFFERED 270
TABLE 273 HITACHI LTD. (HITACHI HIGH-TECH CORPORATION): DEALS JANUARY 2021? OCTOBER 2024 271
TABLE 274 SUMITOMO HEAVY INDUSTRIES, LTD.: COMPANY OVERVIEW 272
TABLE 275 SUMITOMO HEAVY INDUSTRIES, LTD.: PRODUCTS/SERVICES/
SOLUTIONS OFFERED 273
TABLE 276 SUMITOMO HEAVY INDUSTRIES LTD.: PRODUCT LAUNCHES JANUARY 2021?OCTOBER 2024 274
TABLE 277 SUMITOMO HEAVY INDUSTRIES LTD.: OTHER DEVELOPMENTS JANUARY 2021?OCTOBER 2024 274
TABLE 278 CARL ZEISS MEDITEC AG (WHOLLY OWNED SUBSIDIARY OF CARL ZEISS AG): COMPANY OVERVIEW 275
TABLE 279 CARL ZEISS MEDITEC AG (WHOLLY OWNED SUBSIDIARY OF CARL ZEISS AG): PRODUCTS/SERVICES/SOLUTIONS OFFERED 277
TABLE 280 CARL ZEISS MEDITEC AG (WHOLLY OWNED SUBSIDIARY OF CARL ZEISS AG): PRODUCT LAUNCHES, JANUARY 2021?OCTOBER 2024 277
TABLE 281 MIM SOFTWARE INC.: COMPANY OVERVIEW 278
TABLE 282 MIM SOFTWARE INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 278
TABLE 283 MIM SOFTWARE INC.: PRODUCT LAUNCHES AND APPROVALS JANUARY 2021?OCTOBER 2024 279
TABLE 284 MIM SOFTWARE INC.: DEALS, JANUARY 2021?OCTOBER 2024 279
TABLE 285 PANACEA MEDICAL TECHNOLOGIES PVT. LTD.: COMPANY OVERVIEW 280
TABLE 286 PANACEA MEDICAL TECHNOLOGIES PVT. LTD.: PRODUCTS/SERVICES/
SOLUTIONS OFFERED 280
TABLE 287 PANACEA MEDICAL TECHNOLOGIES PVT. LTD.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021?OCTOBER 2024 281
TABLE 288 PROVISION HEALTHCARE: COMPANY OVERVIEW 282
TABLE 289 PROVISION HEALTHCARE: PRODUCTS/SERVICES/SOLUTIONS OFFERED 282
TABLE 290 MEVION MEDICAL SYSTEMS: COMPANY OVERVIEW 283
TABLE 291 MEVION MEDICAL SYSTEMS: PRODUCTS/SERVICES/SOLUTIONS OFFERED 283
TABLE 292 MEVION MEDICAL SYSTEMS: PRODUCT LAUNCHES JANUARY 2021?OCTOBER 2024 284
TABLE 293 MEVION MEDICAL SYSTEMS: DEALS, JANUARY 2021?OCTOBER 2024 284
TABLE 294 RAYSEARCH LABORATORIES: COMPANY OVERVIEW 286
TABLE 295 RAYSEARCH LABORATORIES: PRODUCTS/SERVICES/SOLUTIONS OFFERED 287
TABLE 296 RAYSEARCH LABORATORIES: PRODUCT LAUNCHES JANUARY 2021?OCTOBER 2024 288
TABLE 297 RAYSEARCH LABORATORIES: DEALS, JANUARY 2021?OCTOBER 2024 288
TABLE 298 KONINKLIJKE PHILIPS N.V.: COMPANY OVERVIEW 290
TABLE 299 KONINKLIJKE PHILIPS N.V.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 291
TABLE 300 KONINKLIJKE PHILIPS N.V.: PRODUCT LAUNCHES, JANUARY 2021?OCTOBER 2024 292
TABLE 301 KONINKLIJKE PHILIPS N.V.: DEALS, JANUARY 2021?OCTOBER 2024 292
TABLE 302 INTRAOP MEDICAL, INC.: COMPANY OVERVIEW 293
TABLE 303 OPTIVUS PROTON THERAPY, INC.: COMPANY OVERVIEW 294
TABLE 304 BEBIG MEDICAL: COMPANY OVERVIEW 295
TABLE 305 P-CURE: COMPANY OVERVIEW 296
TABLE 306 THERAGENICS CORPORATION: COMPANY OVERVIEW 297
TABLE 307 PROTOM INTERNATIONAL: COMPANY OVERVIEW 298
TABLE 308 DOSISOFT SA: COMPANY OVERVIEW 29